Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iMMunoPET: 89Zr-daratumumab in Multiple Myeloma
NCT04814615Phase 2Recruiting
- Sponsor
- Hoag Memorial Hospital Presbyterian
- Start
- Mar 2021
- Primary completion
- Jan 2026
- Modality
- Antibody-Radionuclide Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zirconium Zr-89-DFO-daratumumab in multiple myeloma (MM), sponsored by Hoag Memorial Hospital Presbyterian. Primary endpoints: 89Zr-daratumumab PET/CT for pre-treatment multiple myeloma imaging up to 3 years, 89Zr-daratumumab PET/CT for post-treatment multiple myeloma imaging up to 3 years and 1 more. Started Mar 2021; status: recruiting.
02
Drugs
zirconium Zr-89-DFO-daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04814615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04814615.